BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 25071108)

  • 1. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
    J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
    J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
    Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
    J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
    Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
    J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
    Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
    Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
    Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
    Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
    Stephens DM; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; LaCasce AS; Barr PM; Knopp MV; Hsi ED; Leonard JP; Kahl BS; Smith SM; Friedberg JW
    Blood; 2019 Oct; 134(15):1238-1246. PubMed ID: 31331918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD012643. PubMed ID: 31525824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.
    Castagna L; Bramanti S; Balzarotti M; Sarina B; Todisco E; Anastasia A; Magagnoli M; Mazza R; Nozza A; Giordano L; Rodari M; Rinifilo E; Chiti A; Santoro A
    Br J Haematol; 2009 May; 145(3):369-72. PubMed ID: 19344403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
    J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.
    Milgrom SA; Dong W; Akhtari M; Smith GL; Pinnix CC; Mawlawi O; Rohren E; Garg N; Chuang H; Yehia ZA; Reddy JP; Gunther JR; Khoury JD; Suki T; Osborne EM; Oki Y; Fanale M; Dabaja BS
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):333-338. PubMed ID: 28068241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients.
    Girinsky T; Aupérin A; Ribrag V; Elleuch M; Fermé C; Bonniaud G; Ruelle C; Alberini JL; Celebic A; Edeline V
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1047-1052. PubMed ID: 25035208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma.
    Iltis A; Eder V; Blasco H; Colombat P; Sénécal D
    Acta Haematol; 2015; 133(2):172-8. PubMed ID: 25301496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.
    Zinzani PL; Broccoli A; Gioia DM; Castagnoli A; Ciccone G; Evangelista A; Santoro A; Ricardi U; Bonfichi M; Brusamolino E; Rossi G; Anastasia A; Zaja F; Vitolo U; Pavone V; Pulsoni A; Rigacci L; Gaidano G; Stelitano C; Salvi F; Rusconi C; Tani M; Freilone R; Pregno P; Borsatti E; Sacchetti GM; Argnani L; Levis A
    J Clin Oncol; 2016 Apr; 34(12):1376-85. PubMed ID: 26884559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
    Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
    Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.